昭衍新药业绩预增超两倍，实验猴价格波动影响持续

Core Viewpoint - The company expects a significant increase in net profit for 2025, while revenue is projected to decline, influenced by rising prices of laboratory monkeys and ongoing share reduction plans by major shareholders [1][2]. Financial Performance - The company forecasts a net profit attributable to shareholders between 233 million to 349 million yuan for 2025, representing a year-on-year increase of 214% to 371%. However, revenue is expected to decline by 13.9% to 22.1% year-on-year. The profit increase is primarily driven by the appreciation of biological assets, such as laboratory monkeys, while the contribution from laboratory service business profits is decreasing [2]. Management Changes - The actual controllers of the company, Feng Yuxia and Zhou Zhiwen, received regulatory warnings in 2024 for failing to timely disclose shareholding changes, and recent share reduction activities are ongoing. The share reduction plan is not yet completed as of January 2026, which may impact the company's equity structure [3]. Financial Condition - The market price of laboratory monkeys significantly increased in the second half of 2025, with prices ranging from 100,000 to 150,000 yuan per monkey, directly boosting the fair value of the company's biological assets. Analysts from Huatai Securities indicate that supply-demand gaps may lead to continued price increases over the next 2 to 3 years, which will affect the company's profit volatility [4]. Project Progress - The company's laboratory facility in Guangzhou has entered the completion acceptance stage, while the Suzhou facility passed CMA certification in July 2025. The commissioning of new bases may enhance service capacity, but attention is needed on order conversion efficiency [5]. Policy and Regulation - The U.S. Biodefense Act, included in the 2026 National Defense Authorization Act, has a five-year buffer period, which limits short-term impacts on Chinese CXO companies. However, long-term geopolitical risks still need to be monitored [6].